Elecoglipron Phase 2 VISTA Trial Investigates Oral GLP-1RA for Obesity and Overweight
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
Abstract
The Phase 2 VISTA trial evaluated oral Elecoglipron as a once-daily GLP-1RA for weight management in adults with obesity or overweight.